FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines in the fields of hemostasis and anti-complement to address serious medical conditions, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference, being held in New York City February 8-9, 2016.
BIO CEO & Investor Conference – Catalyst Biosciences Presentation Details
Date: Tuesday, February 9, 2016
Time: 8:00 a.m. Eastern Time
Location: Waldorf Astoria, Conrad Room
About Catalyst Biosciences, Inc.
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration (Dry AMD), a condition that can cause visual impairment or blindness for which there are no approved treatments. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
All statements, other than statement of historical facts, included in this press release regarding our strategy, future operations, and plans, including statements relating to the development of the Company’s products, are forward-looking statements. Actual results or events could differ materially from expectations in the forward-looking statements due to various important factors, such as the risk that that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of Catalyst's products, and other risks described in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2015. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.
Investors: Andrew McDonald Managing Director LifeSci Advisors, LLC 646.597.6987 [email protected] Fletcher Payne, CFO Catalyst Biosciences, Inc. 650.871.0761 [email protected] Media: Denise Powell Red House Consulting, LLC 510.703.9491 [email protected]
